News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karo Bio AB: First Patient Included in Phase III Study



10/4/2011 9:40:20 AM

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio (STO:KARO): The first patient has now been included in Karo Bio's phase III trial (the AKKA study) with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES